Welcome to our dedicated page for Betterlife Pharma news (Ticker: BETRF), a resource for investors and traders seeking the latest updates and insights on Betterlife Pharma stock.
BetterLife Pharma Inc. (OTCQB: BETRF) is an emerging biotechnology company whose news flow centers on the development of its proprietary non-hallucinogenic compounds for neuro-psychiatric and neurological disorders. Company announcements highlight scientific data, intellectual property milestones, corporate developments and financing-related transactions tied to its lead assets BETR-001 and BETR-002.
News releases frequently cover scientific and clinical pathway updates, such as preclinical results on BETR-001’s neuroplastogenic activity, mechanistic data on serotonin receptor engagement, and progress through IND-enabling studies. BetterLife also reports on regulatory interactions, including pre-IND meetings with the FDA, and outlines its expectations for future IND filings and potential human trials, as described in its own communications.
Another recurring theme in BetterLife’s news is intellectual property and partnering activity. The company has announced the grant of a composition of matter patent for BETR-001 by the USPTO and references earlier synthesis patents on 2-bromo-LSD. It also issues updates on strategic engagements, such as its agreement with Shanghai-based YAFO Capital to pursue partnering opportunities for BETR-001 in the Greater China region and participation in international life sciences and investment forums.
Investors and observers will also find corporate and capital markets updates, including board and advisory appointments, debt settlements and conversions into equity, and commentary on management share ownership and regulatory matters. Together, these news items provide a view into how BetterLife is advancing its pipeline, managing its capital structure and positioning its non-hallucinogenic neuroplastogens within the broader neuro-psychiatric treatment landscape, based on the company’s own disclosures.
BetterLife Pharma Inc. announces progress in its IND-enabling studies for BETR-001, a non-hallucinogenic LSD derivative for mental disorders. The company has initiated GLP studies for metabolism and genotoxicity. BETR-001 has shown robust activity in animal models without hallucinogenic effects. BetterLife plans to file the IND application with the FDA by the end of 2024.
In March 2024, BetterLife disclosed its intention to conduct private placement offerings of Convertible Debentures to fund the development of BETR-001. The company closed a tranche of $30,000 10% Convertible Debentures with a two-year maturity to further advance BETR-001 development. Each Convertible Debenture is convertible into units of the company, including one common share and one share purchase warrant.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.